vs

Side-by-side financial comparison of Fortress Biotech, Inc. (FBIO) and Linde plc (LIN). Click either name above to swap in a different company.

Fortress Biotech, Inc. is the larger business by last-quarter revenue ($16.1M vs $8.8M, roughly 1.8× Linde plc). On growth, Linde plc posted the faster year-over-year revenue change (8.2% vs 6.3%). Over the past eight quarters, Fortress Biotech, Inc.'s revenue compounded faster (11.0% CAGR vs -96.7%).

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

Linde is a global multinational chemical company and the world's largest industrial gas supplier by market share and revenue. Founded by German scientist and engineer Carl von Linde in 1879 in Wiesbaden, Germany, the company is now headquartered in Woking, United Kingdom, and registered in Ireland as Linde plc. Linde plc was formed in 2018 through the merger of Linde AG and Praxair, which was founded in 1907 in the United States as Linde Air Products Company.

FBIO vs LIN — Head-to-Head

Bigger by revenue
FBIO
FBIO
1.8× larger
FBIO
$16.1M
$8.8M
LIN
Growing faster (revenue YoY)
LIN
LIN
+2.0% gap
LIN
8.2%
6.3%
FBIO
Faster 2-yr revenue CAGR
FBIO
FBIO
Annualised
FBIO
11.0%
-96.7%
LIN

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
FBIO
FBIO
LIN
LIN
Revenue
$16.1M
$8.8M
Net Profit
$-3.9M
Gross Margin
66.1%
48.5%
Operating Margin
-28.8%
27.8%
Net Margin
-24.5%
Revenue YoY
6.3%
8.2%
Net Profit YoY
41.8%
EPS (diluted)
$-0.15
$3.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FBIO
FBIO
LIN
LIN
Q1 26
$8.8M
Q4 25
$16.1M
$8.8B
Q3 25
$17.6M
$8.6B
Q2 25
$16.4M
$8.5B
Q1 25
$13.1M
$8.1B
Q4 24
$15.1M
$8.3B
Q3 24
$14.6M
$8.4B
Q2 24
$14.9M
$8.3B
Net Profit
FBIO
FBIO
LIN
LIN
Q1 26
Q4 25
$-3.9M
$1.5B
Q3 25
$5.8M
$1.9B
Q2 25
$15.5M
$1.8B
Q1 25
$-10.6M
$1.7B
Q4 24
$-6.8M
$1.7B
Q3 24
$-12.9M
$1.6B
Q2 24
$-10.9M
$1.7B
Gross Margin
FBIO
FBIO
LIN
LIN
Q1 26
48.5%
Q4 25
66.1%
Q3 25
67.4%
Q2 25
69.9%
Q1 25
63.5%
Q4 24
69.1%
Q3 24
69.4%
Q2 24
61.6%
Operating Margin
FBIO
FBIO
LIN
LIN
Q1 26
27.8%
Q4 25
-28.8%
23.0%
Q3 25
-38.6%
27.5%
Q2 25
-222.2%
27.7%
Q1 25
-169.9%
26.9%
Q4 24
-158.3%
27.4%
Q3 24
-151.0%
25.0%
Q2 24
-186.5%
26.4%
Net Margin
FBIO
FBIO
LIN
LIN
Q1 26
Q4 25
-24.5%
17.5%
Q3 25
33.2%
22.4%
Q2 25
94.4%
20.8%
Q1 25
-80.6%
20.6%
Q4 24
-44.7%
20.8%
Q3 24
-88.0%
18.5%
Q2 24
-73.5%
20.1%
EPS (diluted)
FBIO
FBIO
LIN
LIN
Q1 26
$3.98
Q4 25
$-0.15
$3.28
Q3 25
$0.11
$4.09
Q2 25
$0.45
$3.73
Q1 25
$-0.48
$3.51
Q4 24
$-0.16
$3.61
Q3 24
$-0.76
$3.22
Q2 24
$-0.73
$3.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FBIO
FBIO
LIN
LIN
Cash + ST InvestmentsLiquidity on hand
$79.4M
$4.0M
Total DebtLower is stronger
$52.4M
$24.7M
Stockholders' EquityBook value
$49.9M
$40.1M
Total Assets
$185.5M
$86.3M
Debt / EquityLower = less leverage
1.05×
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FBIO
FBIO
LIN
LIN
Q1 26
$4.0M
Q4 25
$79.4M
$5.1B
Q3 25
$86.2M
$4.5B
Q2 25
$74.4M
$4.8B
Q1 25
$91.3M
$5.3B
Q4 24
$57.3M
$4.8B
Q3 24
$58.9M
$5.2B
Q2 24
$76.2M
$4.6B
Total Debt
FBIO
FBIO
LIN
LIN
Q1 26
$24.7M
Q4 25
$52.4M
$20.7B
Q3 25
$47.8M
$18.6B
Q2 25
$50.0M
$19.7B
Q1 25
$56.4M
$17.6B
Q4 24
$58.0M
$15.3B
Q3 24
$52.5M
$17.5B
Q2 24
$67.0M
$16.9B
Stockholders' Equity
FBIO
FBIO
LIN
LIN
Q1 26
$40.1M
Q4 25
$49.9M
$38.2B
Q3 25
$55.9M
$38.6B
Q2 25
$43.9M
$38.5B
Q1 25
$22.3M
$38.0B
Q4 24
$22.7M
$38.1B
Q3 24
$21.2M
$39.2B
Q2 24
$17.9M
$38.2B
Total Assets
FBIO
FBIO
LIN
LIN
Q1 26
$86.3M
Q4 25
$185.5M
$86.8B
Q3 25
$181.4M
$86.0B
Q2 25
$159.9M
$86.1B
Q1 25
$178.1M
$82.7B
Q4 24
$144.2M
$80.1B
Q3 24
$127.1M
$82.5B
Q2 24
$145.7M
$80.2B
Debt / Equity
FBIO
FBIO
LIN
LIN
Q1 26
0.62×
Q4 25
1.05×
0.54×
Q3 25
0.86×
0.48×
Q2 25
1.14×
0.51×
Q1 25
2.53×
0.46×
Q4 24
2.55×
0.40×
Q3 24
2.48×
0.45×
Q2 24
3.75×
0.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FBIO
FBIO
LIN
LIN
Operating Cash FlowLast quarter
$-12.5M
Free Cash FlowOCF − Capex
$898.0K
FCF MarginFCF / Revenue
10.2%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$4.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FBIO
FBIO
LIN
LIN
Q1 26
Q4 25
$-12.5M
$3.0B
Q3 25
$-6.1M
$2.9B
Q2 25
$-27.6M
$2.2B
Q1 25
$-19.6M
$2.2B
Q4 24
$-12.9M
$2.8B
Q3 24
$-20.1M
$2.7B
Q2 24
$-21.8M
$1.9B
Free Cash Flow
FBIO
FBIO
LIN
LIN
Q1 26
$898.0K
Q4 25
$1.6B
Q3 25
$1.7B
Q2 25
$954.0M
Q1 25
$891.0M
Q4 24
$1.6B
Q3 24
$1.7B
Q2 24
$796.0M
FCF Margin
FBIO
FBIO
LIN
LIN
Q1 26
10.2%
Q4 25
17.9%
Q3 25
19.4%
Q2 25
11.2%
Q1 25
11.0%
Q4 24
18.8%
Q3 24
19.9%
Q2 24
9.6%
Capex Intensity
FBIO
FBIO
LIN
LIN
Q1 26
Q4 25
16.6%
Q3 25
14.8%
Q2 25
14.8%
Q1 25
15.7%
Q4 24
15.1%
Q3 24
0.0%
12.8%
Q2 24
13.7%
Cash Conversion
FBIO
FBIO
LIN
LIN
Q1 26
Q4 25
1.98×
Q3 25
-1.04×
1.53×
Q2 25
-1.78×
1.25×
Q1 25
1.29×
Q4 24
1.63×
Q3 24
1.76×
Q2 24
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons